Pembrolizumab is indicated as monotherapy for the treatment of NSCLC, locally advanced or metastatic, in adults whose tumors express PD-L1 with an STP ≥ 1% and who have previously received at least one chemotherapy regimen. Here, CD274 is linked to non-small cell lung carcinoma.